ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Silvr, another piece to the puzzle. The Journal of the Endocrine Society published The Impact of Testosterone Therapy on Cardiovascular Risk among Post-Menopausal Women today.

Main Conclusions
Existing research provides promising insights into the benefits of low-dose testosterone therapy, typically combined with estrogen therapy. These benefits may include positive impacts on body composition, functional capacity, insulin sensitivity, inflammatory markers, and cholesterol. However, there remains a substantial lack of knowledge surrounding the effects and mechanisms behind testosterone therapy in post-menopausal women in relation to its impacts on cardiovascular risk. High-quality, evidence-based clinical intervention research is needed to investigate testosterone therapy’s potential implication on cardiovascular risk factors in post-menopausal women.

Should make for an interesting few weeks.

Potential Catalysts approaching:

- October 27th, Clinical trial deadline for submitting results and AbbVie earnings
- November 8th, ANIP Earnings.
- November 11th-13th, American Heart Association - Scientific Sessions